TY - JOUR
T1 - Prognostic impact of Breslow thickness in acral melanoma
T2 - A retrospective analysis
AU - Wei, Xiaoting
AU - Chen, Yu
AU - Yao, Hong
AU - Wu, Di
AU - Li, Hang
AU - Zhang, Rui
AU - Chi, Zhihong
AU - Cui, Chuanliang
AU - Bai, Xue
AU - Mao, Lili
AU - Qi, Zhonghui
AU - Li, Ke
AU - Lan, Shijie
AU - Chen, Lizhu
AU - Guo, Rui
AU - Yao, Xinyu
AU - Lian, Bin
AU - Kong, Yan
AU - Dai, Jie
AU - Tang, Bixia
AU - Wang, Xuan
AU - Gershenwald, Jeffrey E.
AU - Balch, Charles M.
AU - Guo, Jun
AU - Si, Lu
N1 - Funding Information:
Funding sources: Supported by the National Natural Science Foundation of China ( 81972566 , 82073011 , 81972562 ), Beijing Natural Science Foundation ( 7202024 ), Beijing Municipal Administration of Hospitals' Ascent Plan ( DFL20181101 ), and Beijing Medical Award Foundation ( YXJL-2020-0889-0106 ).
Publisher Copyright:
© 2022 American Academy of Dermatology, Inc.
PY - 2022/12
Y1 - 2022/12
N2 - Background: Evidence for the prognostic importance of tumor thickness in acral melanoma (AM) patients is limited. Objective: The objective of the study was to determine the prognostic impact of Breslow thickness in AM. Methods: This multicenter study enrolled patients diagnosed with localized AM between January 1, 2000 and December 31, 2017. Melanoma-specific survival (MSS) in different tumor thickness strata (T1-T4: ≤1, >1-2, >2-4, >4 mm, respectively) was estimated by the Kaplan-Meier method. Comparisons were performed by the log-rank test and multivariable Cox regression. Results: A total of 853 patients with clinical N0 (cN0) AM were included in the analysis. The median follow-up time was 60.1 months. The median MSS in patients with T1-T4 disease was not reached, 111.0, 92.8, and 67.1 months, respectively. MSS differed significantly among cN0 patients with T1-T3 AM (log-rank P = .004,. 012, <0.001 for T1 vs T2, T2 vs T3, and T1 vs T3, respectively); however, there was no significant difference between T3 and T4 AM (hazard ratio = 0.82, 95% CI, 0.62-1.09). Six-subgroup analyses confirmed that survival outcomes were similar between different subgroups with tumor thickness >2 mm. Limitations: The limitations were retrospective design and some missing variables. Conclusions: There was no association between tumor thickness and survival in AM patients with a Breslow thickness >2 mm.
AB - Background: Evidence for the prognostic importance of tumor thickness in acral melanoma (AM) patients is limited. Objective: The objective of the study was to determine the prognostic impact of Breslow thickness in AM. Methods: This multicenter study enrolled patients diagnosed with localized AM between January 1, 2000 and December 31, 2017. Melanoma-specific survival (MSS) in different tumor thickness strata (T1-T4: ≤1, >1-2, >2-4, >4 mm, respectively) was estimated by the Kaplan-Meier method. Comparisons were performed by the log-rank test and multivariable Cox regression. Results: A total of 853 patients with clinical N0 (cN0) AM were included in the analysis. The median follow-up time was 60.1 months. The median MSS in patients with T1-T4 disease was not reached, 111.0, 92.8, and 67.1 months, respectively. MSS differed significantly among cN0 patients with T1-T3 AM (log-rank P = .004,. 012, <0.001 for T1 vs T2, T2 vs T3, and T1 vs T3, respectively); however, there was no significant difference between T3 and T4 AM (hazard ratio = 0.82, 95% CI, 0.62-1.09). Six-subgroup analyses confirmed that survival outcomes were similar between different subgroups with tumor thickness >2 mm. Limitations: The limitations were retrospective design and some missing variables. Conclusions: There was no association between tumor thickness and survival in AM patients with a Breslow thickness >2 mm.
KW - acral melanoma
KW - prognostic impact
KW - staging
KW - thickness
KW - ulceration
UR - http://www.scopus.com/inward/record.url?scp=85139021587&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139021587&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2022.08.052
DO - 10.1016/j.jaad.2022.08.052
M3 - Article
C2 - 36075285
AN - SCOPUS:85139021587
SN - 0190-9622
VL - 87
SP - 1287
EP - 1294
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 6
ER -